Market closedNon-fractional
Vaxart/VXRT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Vaxart
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Ticker
VXRT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
109
Website
vaxart.com
Vaxart Metrics
BasicAdvanced
$154M
Market cap
-
P/E ratio
-$0.53
EPS
0.65
Beta
-
Dividend rate
Price and volume
Market cap
$154M
Beta
0.65
Financial strength
Current ratio
3.137
Quick ratio
2.637
Long term debt to equity
33.317
Total debt to equity
42.58
Interest coverage (TTM)
-39.48%
Management effectiveness
Return on assets (TTM)
-46.82%
Return on equity (TTM)
-112.40%
Valuation
Price to revenue (TTM)
11.708
Price to book
2.15
Price to tangible book (TTM)
2.54
Price to free cash flow (TTM)
-1.531
Growth
Revenue change (TTM)
1,174.75%
Earnings per share change (TTM)
-35.64%
3-year revenue growth (CAGR)
75.28%
3-year earnings per share growth (CAGR)
5.05%
What the Analysts think about Vaxart
Analyst Ratings
Majority rating from 3 analysts.
Vaxart Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.1M
-34.38%
Net income
-$24M
41.04%
Profit margin
-1,161.90%
114.92%
Vaxart Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.16
-$0.11
-$0.12
-$0.14
-
Expected
-$0.18
-$0.18
-$0.15
-$0.14
-$0.15
Surprise
-11.11%
-37.74%
-17.24%
0.00%
-
Vaxart News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vaxart stock?
Vaxart (VXRT) has a market cap of $154M as of July 27, 2024.
What is the P/E ratio for Vaxart stock?
The price to earnings (P/E) ratio for Vaxart (VXRT) stock is 0 as of July 27, 2024.
Does Vaxart stock pay dividends?
No, Vaxart (VXRT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Vaxart dividend payment date?
Vaxart (VXRT) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxart?
Vaxart (VXRT) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Vaxart stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.